Endometrial carcinoma: genes and variants
Explore variant evidence for Endometrial carcinoma across 9 analyzed proteins (MSH6, CDH1, PMS2, MSH3, MLH3 and 4 more). Linked ClinVar records include 4 pathogenic or likely pathogenic variants, 461 variants of uncertain significance and 48 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-10-21. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Endometrial carcinoma
MSH6: DNA mismatch repair protein Msh6
Together with MSH2, it recognizes single-base mismatches and small insertion-deletion loops during DNA replication and initiates mismatch repair. Germline loss-of-function variants cause Lynch syndrome, while biallelic variants can cause constitutional mismatch-repair deficiency.
1 ClinVar pathogenic / likely pathogenic and 123 uncertain variants in MSH6 have source records linked to Endometrial carcinoma. Association strength is not clinical gene validity.
CDH1: Cadherin-1
Its E-cadherin-mediated adhesion preserves epithelial architecture and suppresses inappropriate cell detachment and invasion. Germline loss-of-function variants cause hereditary diffuse gastric cancer syndrome and substantially increase diffuse gastric and lobular breast-cancer risk.
1 ClinVar pathogenic / likely pathogenic and 20 uncertain variants in CDH1 have source records linked to Endometrial carcinoma. Association strength is not clinical gene validity.
PMS2: Mismatch repair endonuclease PMS2
Together with MLH1, it provides endonuclease activity needed to complete DNA mismatch repair after replication errors are recognized. Germline loss-of-function variants cause Lynch syndrome, while biallelic variants cause constitutional mismatch-repair deficiency.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PMS2 have source records linked to Endometrial carcinoma. Association strength is not clinical gene validity.
MSH3: DNA mismatch repair protein Msh3
Together with MSH2, it recognizes larger insertion-deletion loops and certain DNA secondary structures during mismatch repair. Variation can modify the behavior of repeat-expansion disorders, while biallelic loss has been associated with a recessive adenomatous-polyposis phenotype.
0 ClinVar pathogenic / likely pathogenic and 365 uncertain variants in MSH3 have source records linked to Endometrial carcinoma. Association strength is not clinical gene validity.
MLH3: DNA mismatch repair protein Mlh3
It partners with other mismatch-repair proteins and also participates in meiotic crossover formation. Biallelic or monoallelic variants have been investigated in cancer predisposition, but the clinical significance of many MLH3 variants remains less firmly established than for core Lynch-syndrome genes.
0 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in MLH3 have source records linked to Endometrial carcinoma. Association strength is not clinical gene validity.
MLH1: DNA mismatch repair protein Mlh1
The protein partners with PMS2 to form MutL alpha, a core complex in post-replicative DNA mismatch repair. By helping correct copying errors in DNA, MLH1 protects genome stability, and inherited MLH1 variants are a major cause of Lynch syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MLH1 have source records linked to Endometrial carcinoma. Association strength is not clinical gene validity.
MSH2: DNA mismatch repair protein Msh2
The protein forms mismatch-recognition complexes with MSH6 or MSH3 that detect base mismatches and insertion-deletion loops in DNA. This first step of mismatch repair helps preserve genome integrity, and inherited MSH2 variants are associated with Lynch syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MSH2 have source records linked to Endometrial carcinoma. Association strength is not clinical gene validity.
PTEN: Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
A lipid and protein phosphatase that removes phosphate groups from signaling molecules, especially PIP3. By opposing the PI3K-AKT pathway, it limits cell growth and survival signals, and PTEN variants are associated with Cowden syndrome and multiple cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PTEN have source records linked to Endometrial carcinoma. Association strength is not clinical gene validity.
PIK3CA: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Its p110-alpha catalytic activity generates PIP3 and activates AKT-dependent growth, survival, and metabolic signaling downstream of many receptors. Activating variants are frequent cancer drivers and, when present mosaically during development, can cause PIK3CA-related overgrowth spectrum.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PIK3CA have source records linked to Endometrial carcinoma. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Endometrial carcinoma
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| MSH6 A1230P | 1230 | Pathogenic / likely pathogenic (★★) | |
| CDH1 K440N | 440 | Cadherin 3 | Pathogenic / likely pathogenic (★) |
| PMS2 N45T | 45 | Pathogenic / likely pathogenic | |
| PIK3CA T1025S | 1025 | PI3K/PI4K catalytic | Pathogenic / likely pathogenic |
Same protein, different disease
- Lynch syndrome also has ClinVar records linked to MSH6 variants; they fall mostly in different places as the Endometrial carcinoma variants (23 pathogenic / likely pathogenic).
- Lynch syndrome also has ClinVar records linked to PMS2 variants; they fall mostly in different places as the Endometrial carcinoma variants (19 pathogenic / likely pathogenic).
- CDH1-related diffuse gastric and lobular breast cancer syndrome also has ClinVar records linked to CDH1 variants; they fall mostly in different places as the Endometrial carcinoma variants (11 pathogenic / likely pathogenic).
- Hereditary diffuse gastric adenocarcinoma also has ClinVar records linked to CDH1 variants; they fall mostly in different places as the Endometrial carcinoma variants (4 pathogenic / likely pathogenic).
- PIK3CA related overgrowth syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Endometrial carcinoma variants (30 pathogenic / likely pathogenic).
- Cowden syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Endometrial carcinoma variants (23 pathogenic / likely pathogenic).
- Megalencephaly-capillary malformation-polymicrogyria syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Endometrial carcinoma variants (22 pathogenic / likely pathogenic).
- Ovarian neoplasm also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Endometrial carcinoma variants (5 pathogenic / likely pathogenic).
- PIK3CA constitutional syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Endometrial carcinoma variants (4 pathogenic / likely pathogenic).
Diseases related to Endometrial carcinoma
- Lynch syndrome, also linked to MLH1, MLH3, MSH2, MSH6 and 1 more
- Ovarian cancer, also linked to CDH1, MLH1, MSH2, MSH6 and 1 more
- Colorectal cancer, also linked to MLH1, MLH3, MSH2, MSH6 and 1 more
- Colon carcinoma, also linked to MLH1, MSH2, MSH6, PIK3CA and 1 more
- Breast and/or ovarian cancer, also linked to CDH1, MLH1, MSH2, MSH6 and 1 more
- Hereditary breast cancer, also linked to CDH1, MLH1, PIK3CA and PTEN
- Hereditary breast ovarian cancer syndrome, also linked to CDH1, MLH1, MSH2 and PMS2
- Gastric cancer, also linked to MLH1, MSH6, PIK3CA and PMS2
- Mismatch repair cancer syndrome, also linked to MLH1, MSH2, MSH6 and PMS2
- Cowden syndrome, also linked to PIK3CA and PTEN
- Muir-Torré syndrome, also linked to MLH1 and MSH2
- Prostate cancer, also linked to CDH1 and PTEN
Frequently asked questions
Which genes have records linked to Endometrial carcinoma?
This view contains 9 analyzed proteins: MSH6, CDH1, PMS2, MSH3, MLH3 and 4 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 4 pathogenic or likely pathogenic variants, 461 variants of uncertain significance and 48 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 544 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center